Endocrine Abstracts

Introduction: Pembrolizumab is an immune checkpoint inhibitor (ICI) used to treat advanced cancers. While improving survival rates, ICIs also cause immune-related adverse events (IRAEs). The endocrine system remains the most vulnerable to IRAEs: thyroid involvement is the commonest while pancreatic involvement is rare, affecting less than 1% of individuals. Risk factors for IRAEs include, personal or family history of autoimmune conditions, presence of another...